Jessica Chan, PA
Physician Assistant · Modesto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Csi Medical Group · 104 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jessica Chan’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G55993 · Cancelled
Licence status: Cancelled · since 1985 · New York Medical College.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$295,261
Medicare paid this office $295,261 for 917 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 496 | $75,089 | $75 |
| Short return visit (20+ min) | 519 | $49,192 | $54 |
| Destruction of precancer skin growth, 15 or more growths | 272 | $48,296 | $109 |
| Destruction of skin growth, 1-14 growths | 357 | $32,574 | $72 |
| Destruction of precancer skin growth, 1 growth | 498 | $24,354 | $34 |
See all 20 services
| Return visit (30+ min) | 496 | $75,089 | $75 |
| Short return visit (20+ min) | 519 | $49,192 | $54 |
| Destruction of precancer skin growth, 15 or more growths | 272 | $48,296 | $109 |
| Destruction of skin growth, 1-14 growths | 357 | $32,574 | $72 |
| Destruction of precancer skin growth, 1 growth | 498 | $24,354 | $34 |
| Destruction of precancer skin growth, 2-14 growths | 418 | $14,074 | $5 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 106 | $10,253 | $66 |
| Shaving of skin growth of body, arms, or legs, 0.5 cm or less | 100 | $6,383 | $45 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 41 | $4,932 | $88 |
| New patient visit (30+ min) | 71 | $3,894 | $55 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 36 | $3,235 | $85 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 42 | $3,046 | $66 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 35 | $2,678 | $70 |
| New patient visit (45+ min) | 28 | $2,561 | $91 |
| Destruction of skin growth, 15 or more growths | 22 | $2,072 | $90 |
| Biopsy of related skin growth, first growth | 30 | $1,704 | $55 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 15 | $1,455 | $86 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 13 | $1,362 | $97 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.5 cm or less | 20 | $1,185 | $54 |
| Photograph of entire body | 17 | $843 | $50 |
Procedures Medicare counted
| Removal of skin lesions | 2253 | More than 98% of doctors who do this |
| Removal or shaving of skin growth | 501 | More than 95% of doctors who do this |
| Skin biopsy | 55 | More than 70% of doctors who do this |
Who their Medicare patients are
917 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 9% · Women 62% · Also on Medicaid 6% · Health risk score 0.89. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 69% · Diabetes 22% · Chronic kidney disease 19% · Coronary heart disease 18% · Cancer 14% · Atrial fibrillation 13% · Depression 12% · COPD 9% · Heart failure 7% · Stroke 4% · Dementia 3%.
The office billed $962,781, Medicare allowed $413,738 and paid $295,261; for 7,474 services of 46 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 917 | 7,474 | 75 | 0.89 | $962,781 | $295,261 |
| 2023 | 474 | 2,333 | 74 | 0.86 | $316,962 | $105,021 |
| 2022 | 640 | 4,676 | 74 | 0.91 | $670,929 | $208,939 |
| 2021 | 660 | 4,196 | 73 | 0.97 | $696,791 | $219,458 |
| 2020 | 150 | 207 | 65 | 1.47 | $108,827 | $14,659 |
| 2019 | 102 | 122 | 63 | 1.42 | $63,328 | $7,634 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 223 | $22,345 | $87 |
| Destruction of precancer skin growth, 15 or more growths | 143 | $20,257 | $118 |
| Short return visit (20+ min) | 221 | $15,631 | $60 |
| Destruction of skin growth, 1-14 growths | 106 | $8,707 | $72 |
| Destruction of precancer skin growth, 1 growth | 172 | $6,641 | $35 |
| New patient visit (30+ min) | 70 | $4,680 | $67 |
| Destruction of precancer skin growth, 2-14 growths | 138 | $4,274 | $5 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 43 | $3,659 | $68 |
| Shaving of skin growth of body, arms, or legs, 0.5 cm or less | 52 | $2,867 | $47 |
| New patient visit (45+ min) | 30 | $2,781 | $93 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 23 | $2,401 | $83 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 28 | $2,321 | $75 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 16 | $1,513 | $80 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.5 cm or less | 15 | $832 | $52 |
2022: 20 services
| Destruction of precancer skin growth, 15 or more growths | 305 | $54,556 | $108 |
| Return visit (30+ min) | 330 | $41,987 | $77 |
| Short return visit (20+ min) | 395 | $30,100 | $52 |
| Destruction of skin growth, 1-14 growths | 167 | $13,188 | $66 |
| Destruction of precancer skin growth, 1 growth | 262 | $11,199 | $33 |
| Destruction of precancer skin growth, 2-14 growths | 234 | $7,930 | $4 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 85 | $7,216 | $63 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 49 | $5,637 | $85 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 13 | $5,315 | None |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 48 | $4,025 | $79 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 42 | $3,486 | $65 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 31 | $3,372 | $84 |
| Application of light with debridement to destroy precancer skin growth | 13 | $3,365 | $198 |
| Shaving of skin growth of body, arms, or legs, 0.5 cm or less | 54 | $3,309 | $55 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 31 | $2,078 | $61 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 13 | $1,920 | $107 |
| New patient visit (30+ min) | 34 | $1,573 | $46 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.5 cm or less | 18 | $1,166 | $61 |
| Biopsy of related skin growth, first growth | 24 | $1,138 | $47 |
| New patient visit (45+ min) | 11 | $855 | $78 |
2021: 24 services
| Destruction of precancer skin growth, 15 or more growths | 265 | $51,781 | $117 |
| Return visit (30+ min) | 239 | $29,939 | $88 |
| Short return visit (20+ min) | 320 | $27,904 | $61 |
| Destruction of skin growth, 1-14 growths | 204 | $18,860 | $72 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 67 | $8,267 | $82 |
| Destruction of precancer skin growth, 1 growth | 180 | $7,649 | $33 |
| New patient visit (45+ min) | 71 | $7,542 | $106 |
| New patient visit (30+ min) | 110 | $7,072 | $64 |
| Destruction of precancer skin growth, 2-14 growths | 172 | $6,983 | $5 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 64 | $5,258 | $65 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 56 | $5,051 | $81 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 39 | $5,003 | $96 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 36 | $3,950 | $94 |
| Emergency department visit with moderate level of medical decision making | 45 | $3,766 | $84 |
| Emergency department visit with high level of medical decision making | 23 | $2,940 | $128 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 36 | $2,759 | $67 |
| Destruction of skin growth, 15 or more growths | 22 | $1,854 | $74 |
| Emergency department visit with low level of medical decision making | 41 | $1,835 | $44 |
| Punch biopsy, first skin growth | 20 | $1,812 | $91 |
| Biopsy of related skin growth, first growth | 19 | $1,139 | $54 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 15 | $1,091 | $68 |
| Shaving of skin growth of body, arms, or legs, 0.5 cm or less | 14 | $792 | $57 |
| Punch biopsy, each additional skin growth | 15 | $664 | $44 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $29 | None |
2020: 3 services
| Emergency department visit with moderate level of medical decision making | 50 | $4,017 | $80 |
| Emergency department visit with high level of medical decision making | 33 | $3,874 | $117 |
| Emergency department visit with low level of medical decision making | 51 | $2,301 | $45 |
2019: 3 services
| Emergency department visit with moderate level of medical decision making | 40 | $3,180 | $79 |
| Emergency department visit with low level of medical decision making | 47 | $2,012 | $42 |
| Emergency department visit with high level of medical decision making | 14 | $1,520 | $109 |
Drugs they prescribed that Part D paid
$565,988
Pharmacies billed $565,988 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,238 generic and 82 brand-name prescriptions · $565,988 in drug cost · 45 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Skyrizi | 13 | $260,304 | $20,023 |
| Dupixent | 23 | $101,099 | $4,396 |
| Otezla | 13 | $62,034 | $4,772 |
| Fluorouracil | 479 | $34,707 | $72 |
| Ketoconazole | 252 | $5,831 | $23 |
See all 18 drugs
| Skyrizi | 13 | $260,304 | $20,023 |
| Dupixent | 23 | $101,099 | $4,396 |
| Otezla | 13 | $62,034 | $4,772 |
| Fluorouracil | 479 | $34,707 | $72 |
| Ketoconazole | 252 | $5,831 | $23 |
| Tacrolimus | 19 | $3,682 | $194 |
| Clobetasol Propionate | 93 | $3,447 | $37 |
| Calcipotriene | 21 | $2,721 | $130 |
| Metronidazole | 36 | $1,937 | $54 |
| Fluocinonide | 16 | $1,548 | $97 |
| Clindamycin Phosphate | 31 | $1,194 | $39 |
| Fluocinolone Acetonide | 12 | $969 | $81 |
| Triamcinolone Acetonide | 87 | $905 | $10 |
| Hydrocortisone | 66 | $694 | $11 |
| Doxycycline Hyclate | 22 | $271 | $12 |
| Mupirocin | 28 | $232 | $8 |
| Valacyclovir | 19 | $171 | $9 |
| Cephalexin | 12 | $137 | $11 |
Year by year
| 2024 | 1,320 | 526 | None | 6% | $565,988 |
| 2023 | 1,721 | 657 | 0% (0) | 7% | $696,862 |
| 2022 | 1,655 | 623 | 0% (0) | 5% | $282,306 |
| 2021 | 1,524 | 665 | 1% (18) | 3% | $128,792 |
| 2020 | 135 | 90 | None | 8% | $3,306 |
| 2019 | 63 | 47 | None | None | $891 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Skyrizi | 14 | $299,147 | $21,368 |
| Otezla | 25 | $114,139 | $4,566 |
| Dupixent | 14 | $51,599 | $3,686 |
| Fluorouracil | 466 | $45,966 | $99 |
| Opzelura | 12 | $26,711 | $2,226 |
| Clobetasol Propionate | 150 | $12,647 | $84 |
| Ketoconazole | 352 | $10,225 | $29 |
| Calcipotriene | 40 | $9,589 | $240 |
| Tacrolimus | 24 | $6,222 | $259 |
| Fluocinonide | 40 | $3,746 | $94 |
| Clindamycin Phosphate | 54 | $3,005 | $56 |
| Metronidazole | 36 | $2,737 | $76 |
| Triamcinolone Acetonide | 153 | $1,667 | $11 |
| Doxycycline Hyclate | 57 | $1,265 | $22 |
| Hydrocortisone | 90 | $867 | $10 |
| Mupirocin | 38 | $495 | $13 |
| Doxycycline Monohydrate | 14 | $494 | $35 |
| Valacyclovir | 17 | $360 | $21 |
| Hydroxyzine | 15 | $150 | $10 |
| Nystatin | 12 | $150 | $12 |
| Cephalexin | 14 | $107 | $8 |
2022: 17 drugs
| Otezla | 26 | $112,680 | $4,334 |
| Fluorouracil | 442 | $56,671 | $128 |
| Clobetasol Propionate | 132 | $11,117 | $84 |
| Ketoconazole | 267 | $7,766 | $29 |
| Calcipotriene | 37 | $6,972 | $188 |
| Tacrolimus | 23 | $6,830 | $297 |
| Doxycycline Hyclate | 70 | $3,230 | $46 |
| Metronidazole | 33 | $3,183 | $96 |
| Fluocinonide | 45 | $2,703 | $60 |
| Clindamycin Phosphate | 48 | $2,236 | $47 |
| Triamcinolone Acetonide | 189 | $2,063 | $11 |
| Hydrocortisone | 152 | $1,213 | $8 |
| Betamethasone Dipropionate | 18 | $1,191 | $66 |
| Mupirocin | 51 | $693 | $14 |
| Valacyclovir | 18 | $317 | $18 |
| Nystatin | 13 | $235 | $18 |
| Cephalexin | 26 | $187 | $7 |
2021: 19 drugs
| Fluorouracil | 356 | $54,349 | $153 |
| Clobetasol Propionate | 146 | $10,508 | $72 |
| Ketoconazole | 202 | $6,420 | $32 |
| Tacrolimus | 18 | $5,359 | $298 |
| Calcipotriene | 22 | $4,610 | $210 |
| Fluocinonide | 55 | $4,016 | $73 |
| Doxycycline Hyclate | 60 | $2,600 | $43 |
| Metronidazole | 29 | $2,322 | $80 |
| Triamcinolone Acetonide | 171 | $1,935 | $11 |
| Clindamycin Phosphate | 25 | $1,411 | $56 |
| Hydrocortisone | 171 | $1,264 | $7 |
| Gentamicin Sulfate | 12 | $578 | $48 |
| Mupirocin | 36 | $446 | $12 |
| Nystatin | 18 | $393 | $22 |
| Hydroxyzine | 20 | $255 | $13 |
| Cephalexin | 36 | $211 | $6 |
| Hydrocodone-Acetaminophen | 16 | $93 | $6 |
| Ibuprofen | 17 | $84 | $5 |
| Cyclobenzaprine | 12 | $44 | $4 |
2020: 2 drugs
| Cephalexin | 21 | $114 | $5 |
| Ibuprofen | 13 | $55 | $4 |
Money from drug and device companies
$1,106 in 2025
| 2025 | 13 | 36 | None | $1,106 |
| 2024 | 14 | 43 | None | $1,124 |
| 2023 | 17 | 69 | None | $2,070 |
| 2022 | 12 | 33 | None | $954 |
| 2021 | 8 | 12 | None | $703 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $521 | 16 payments
|
| Boston Scientific | General - Pain Management | $131 | 1 payment
|
| Abbvie | Skyrizi | $110 | 4 payments
|
| Incyte | Opzelura | $67 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $66 | 3 payments
|
| LEO Pharma | Adbry | $43 | 2 payments
|
See all 36 published payments
| Novartis Pharmaceuticals | Meals · 2025-12-16 | Cosentyx | $18 |
| Janssen Biotech | Meals · 2025-12-11 | Tremfya | $18 |
| Novartis Pharmaceuticals | Meals · 2025-11-19 | Cosentyx | $27 |
| Abbvie | Meals · 2025-11-19 | Skyrizi | $26 |
| Janssen Biotech | Meals · 2025-11-12 | Tremfya | $20 |
| Novartis Pharmaceuticals | Meals · 2025-11-05 | Rhapsido | $21 |
| Boston Scientific | Meals · 2025-10-29 | General - Pain Management | $131 |
| Incyte | Meals · 2025-10-29 | Opzelura | $18 |
| Organon | Meals · 2025-10-27 | Vtama | $3 |
| Abbvie | Meals · 2025-10-22 | Skyrizi | $26 |
| Janssen Biotech | Meals · 2025-10-16 | Tremfya | $24 |
| LEO Pharma | Meals · 2025-10-15 | Anzupgo | $17 |
| Janssen Biotech | Meals · 2025-10-03 | Tremfya | $37 |
| Janssen Biotech | Education · 2025-09-30 | Tremfya | $83 |
| Incyte | Meals · 2025-09-03 | Opzelura | $26 |
| Janssen Biotech | Meals · 2025-08-14 | Tremfya | $24 |
| LEO Pharma | Meals · 2025-08-06 | Adbry | $26 |
| Janssen Biotech | Meals · 2025-07-23 | Tremfya | $39 |
| Botanix SB | Meals · 2025-07-02 | Sofdra | $21 |
| Ucb | Meals · 2025-06-12 | Bimzelx | $29 |
| Janssen Biotech | Education · 2025-06-09 | Tremfya | $80 |
| Genzyme | Meals · 2025-05-28 | Dupixent | $36 |
| Janssen Biotech | Meals · 2025-05-22 | Tremfya | $32 |
| Janssen Biotech | Meals · 2025-05-13 | Tremfya | $25 |
| Abbvie | Meals · 2025-05-01 | Skyrizi | $29 |
| Janssen Biotech | Meals · 2025-04-10 | Tremfya | $26 |
| Helsinn Therapeutics (U.S.) | Meals · 2025-04-03 | Valchlor | $14 |
| Incyte | Meals · 2025-04-03 | Opzelura | $23 |
| Abbvie | Meals · 2025-03-26 | Skyrizi | $30 |
| Janssen Biotech | Meals · 2025-03-13 | Tremfya | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-03-06 | Dupixent | $37 |
| Janssen Biotech | Meals · 2025-02-26 | Tremfya | $3 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $24 |
| Pfizer | Meals · 2025-02-06 | Cibinqo | $28 |
| Janssen Biotech | Meals · 2025-01-21 | Tremfya | $33 |
| Janssen Biotech | Meals · 2025-01-16 | Tremfya | $27 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,124
| Janssen Biotech | Tremfya | $431 | 12 payments
|
| Abbvie | Skyrizi | $180 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $100 | 4 payments
|
| Incyte | Opzelura | $69 | 4 payments
|
| Amgen | Otezla | $62 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $59 | 2 payments
|
| LEO Pharma | Adbry | $48 | 2 payments
|
| Ucb | Bimzelx | $39 | 2 payments
|
| Janssen Scientific Affairs | Tremfya | $32 | 1 payment
|
| Dermavant Sciences | Vtama | $30 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $21 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Valchlor | $20 | 1 payment
|
| Sun Pharmaceutical Industries | Winlevi | $20 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $13 | 1 payment
|
2023: $2,070
| Incyte | Opzelura | $288 | 10 payments
|
| Janssen Biotech | Tremfya | $278 | 12 payments
|
| Dermavant Sciences | Vtama | $275 | 5 payments
|
| Abbvie | Skyrizi | $268 | 9 payments
|
| Arcutis Biotherapeutics | None | $213 | 9 payments
|
| Regeneron Healthcare Solutions | Dupixent | $205 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $142 | 5 payments
|
| LEO Pharma | Adbry | $117 | 1 payment
|
| Genzyme | Dupixent | $82 | 3 payments
|
| STRATA Skin Sciences | Xtrac | $38 | 2 payments
|
| Amgen | Otezla | $35 | 1 payment
|
| Pfizer | Eucrisa | $30 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $26 | 2 payments
|
| Ucb | Cimzia | $21 | 1 payment
|
| Almirall | Klisyri | $20 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $20 | 1 payment
|
| Janssen Scientific Affairs | Tremfya | $14 | 1 payment
|
2022: $954
| Incyte | Opzelura | $203 | 8 payments
|
| Abbvie | Skyrizi | $185 | 6 payments
|
| Sun Pharmaceutical Industries | Ilumya | $175 | 7 payments
|
| Amgen | Otezla | $143 | 2 payments
|
| Journey Medical | None | $59 | 1 payment
|
| Genzyme | Dupixent | $48 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $40 | 1 payment
|
| Genentech USA | Erivedge | $23 | 1 payment
|
| Lilly USA | Taltz | $22 | 1 payment
|
| Janssen Biotech | Tremfya | $21 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $19 | 1 payment
|
| Galderma Laboratories L.P. | Aklief | $15 | 1 payment
|
2021: $703
| Genzyme | Dupixent | $232 | 3 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $166 | 1 payment
|
| AbbVie | Skyrizi | $88 | 2 payments
|
| Galderma Laboratories L.P. | Aklief | $63 | 1 payment
|
| Pfizer | Eucrisa | $54 | 2 payments
|
| VYNE Pharmaceuticals | Zilxi | $53 | 1 payment
|
| Janssen Biotech | Tremfya | $26 | 1 payment
|
| Lilly USA | Taltz | $21 | 1 payment
|
Professional record
- NPI
- 1164992277
- Licence
- CA 55993California G55993: Cancelled
- Group
- Csi Medical Group
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1700 Coffee Rd, Modesto, CA, 95355
- NPI first listed
- 2018-12-01
- NPI last updated
- 2024-11-21
- NPI record certified
- 2024-11-21
This is when the NPI record was last certified, not a medical board exam.